Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons with Dementia
Neurol 105: e213717, Zissimopoulos, J.,et al, 2025
"Noncognitive" Symptoms of Early Alzheimer Disease
Neurol 84:617-622, Masters, M.C.,et al, 2015
Assessment and Management of Behavioral and Psychological Symptoms of Dementia
BMJ 350:h369, Kales, H.C.,et al, 2015
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
NEJM 371:1369-1373, Okun, M.S., 2014
Degenerative Diseases of the Nervous System, Alzheimer Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1063, Ropper, A.H.,et al, 2014
Antidepressant Treatment in Alzheimers Disease
Lancet 378:375-378, Brodaty, H., 2011
Early Alzheimers Disease
NEJM 362:2194-2201, Mayeux,R., 2010
Disclosure of APOE Genotype for Risk of Alzheimers Disease
NEJM 361:245-254,298, Green,R.C.,et al, 2009
Prodromal Alzheimers Disease: Successive Emergence of the Clinical Symptoms
Ann Neurol 64:492-498,479, Amieva,H.,et al, 2008
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Potentially Reversible Conditions in 1000 Consecutive Memory Clinic Patients
JNNP 73:390-394, Hejl,A.,et al, 2002
An 80-Year-Old Man With Memory Loss
JAMA 283:1046-1053, Larson,E.B., 2000
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
What Are the Obstacles for an Accurate Clinical Diagnosis of Pick's Disease
Neurol 49:62-69, Litvan,I.,et al, 1997
Clinical Features and Pharmacologic Treatment of Behavioral Symptoms of Alzheimer's Disease
Neurol 48 (Suppl 6) :S17-S24997., Borson,S.&Raskind,M.A., 1997
The Family Caregiver's Role in Alzheimer's Disease
Neurol 48 (Suppl 6) :S25-S29997., Haley,W.E., 1997
Diagnosis and Treatment of Alzheimer Disease and Related Disorders
JAMA 278:1363-1371, Small,G.W.,et al, 1997
Management of the Behavioral Manifestations of Dementia
Arch Int Med 155:250-260, Yeager,B.F.,et al, 1995
Extrapyramidalism in Alzheimer's Disease:Prevalence, Psychiatric and Neuropsychological Correlates
JNNP 57:1503-1509, Merello,M.,et al, 1994
Pick's Disease Versus Alzheimer's Disease:A Comparison of Clinical Characteristics
Neurol 43:289-292, Mendez,M.F.,et al, 1993
Differential Diagnosis in Dementia, Principal Components Analysis of Clinical Data From a Population Survey
Arch Neurol 50:72-77, Jorm,A.F.,et al, 1993
Personality Changes in Alzheimer's Disease
Arch Neurol 49:486-491, Chatterjee,A.,et al, 1992
Effects of a Training Programme to Reduce Stress in Carers of Patients with Dementia
BMJ 299:1375-1379, Brodaty,H.&Gresham,M., 1989
The Psychiatric Symptoms of Alzheimer's Disease
J Am Geriatr Soc 36:7-12, Merriam,A.E.,et al, 1988
Genetic Linkage in Neurologic Diseases
Editorial, NEJM 316:1018-10201987., Martin,J.B., 1987
Risk Factors for Alzheimer's Disease:A Case-Control Study
Neurol 37:1630-1633, Shalat,S.T.,et al, 1987
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021
Diagnosis and Management of Dementia
JAMA 322:1589-1599, Arvanitakis, Z.,et al, 2019
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Patients with Rosacea have Increased Risk of Dementia
Ann Neurol 79:921-928, Egeberg, A.,et al, 2016
Plasma Levels of Apolipoprotein E and Risk of Dementia in the General Population
Ann Neurol 77:301-311, Rasmussen, K.L.,et al, 2015
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Dementia: Timely Diagnosis and Early Intervention
BMJ 350:h3029, Robinson, L.,et al, 2015
Effect of Dextromethorphan-Quinidine on Agitation in Patients with Alzheimer Disease Dementia
JAMA 314:1242-1254, Cummings, J.L.,et al, 2015